FIGURE 5.

DU145 stem cell‐like (SCL) cells generate docetaxel/fenofibrate (DCX/FF)‐sensitive offspring. A,B, dcx/ffSCL_DU145 and dcx/ffSCL_DCX20 cells were cultivated in the presence of DCX and/or FF (10 nM/25 μM). Their motility (A), proliferation, and apoptotic response (B) was quantified after 6, 48 and 72 hours, respectively. C, Cells were cultivated as in A and the architecture of microtubular cytoskeleton was estimated after 48 hours of in DCX/FF treatment. Scale bar = 50 μm. D, DU145_DCX20 cells were subcutaneously injected into abdominal flank of Severe Combined ImmunoDeficiency (SCID) mice and the growth of tumors was estimated for 2 to 4 weeks in the presence/absence of DCX (10 mg/kg) and FF (60 mg/kg). At least 10 animals were taken for each variant (N > 10). E, The morphology and displacement of dfSCL_DU145 and _DCX20 cells quantified after 48 hours of DCX or DCX/FF treatment. Scale bar = 50 μm. F, Doubling times and motility rates of naïve DU145 cell lineages and their SCL counterparts. The statistical significance of the differences was tested with t‐Student test (D and proliferation in B, F; #P ≤ .05 vs untreated control; *P ≤ .05 vs wild‐type [WT] lineage(s) or selected bars, or by one‐way ANOVA followed by post hoc Tukey's HSD (A and motility in B, E, F; *P ≤ .05 vs WT lineage(s); #P ≤ .05 vs untreated control). All results are representative of a least three independent experiments (N ≥ 3). Note the increased DCX‐resistance and slightly reduced sensitivity of dfSCL_DU145 lineages to the combined DCX/FF treatment